UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Dropout Assumptions
In a report published Thursday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised the price target from $41.00 to $52.00.
In the report, Karnauskas noted, “AEGR has made assumptions for dropouts, which are key to their guidance of ending the year with 250-300 patients on Juxtapid. While our analysis suggests the co is well on track to beat the guidance, Aegerion wants to be conservative and get more data on dropouts ahead of modifying guidance. Dropout color might come later in the year when the co has more data (too soon for 1Q13 call). While the ph 3 saw 20% drop outs, AEGR expects much lower.”
Aegerion Pharmaceuticals closed on Wednesday at $38.49.
Latest Ratings for AEGR
|Feb 2016||Bank of America||Downgrades||Neutral||Underperform|
|Nov 2015||Bank of America||Upgrades||Underperform||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.